ArticleFrontiers in pharmacology2026
Integrating network analysis and machine learning to explore the pharmacological targets and associations of oleanolic acid in lung adenocarcinoma.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung adenocarcinoma (LUAD), a major type of non-small cell lung cancer, has high incidence and mortality rates. Oleanolic acid (OA), a natural pentacyclic triterpene compound, has demonstrated potential anti-tumor effects but its pharmacological effects in LUAD remain unclear. Purpose: This study aims to identify the potential targets and action pathways of OA in LUAD using network analysis, transcriptomics, molecular docking, animal experiments, and preliminary clinical sample assessment. Methods: Potential candidate genes for OA in LUAD were identified from public databases including PubChem, GeneCards, and TCGA. GO and KEGG enrichment analyses were performed using Metascape, and a PPI network was constructed. Machine learning methods (Lasso regression and SVM-RFE) were employed to refine the candidate genes and identify key biomarkers. Prognostic, clinicopathological, GSEA, mutation, and immune infiltration analyses were conducted. Molecular docking was performed to estimate the theoretical binding affinity between OA and the biomarkers, which was further evaluated using animal models and clinical samples. Results: 21 candidate genes were initially identified, with TOP2A and ALOX5AP emerging as key biomarkers. High TOP2A expression and low ALOX5AP expression were associated with poor prognosis. GSEA showed co-enrichment in the IgA production pathway. Mutation analysis indicated higher amplification propensity for TOP2A. Both biomarkers correlated with immune cells. Molecular docking and animal experiments suggested OA's regulatory effects on these genes, with clinical sample evaluation. Conclusion: Utilizing computational screening as a theoretical starting point alongside preliminary experimental evaluations, this study identifies ALOX5AP and TOP2A as potential pharmacological biomarkers associated with OA treatment in LUAD. Rather than asserting definitive specific targeting, these findings provide preliminary associative evidence. Although direct causal relationships require further functional investigation, this work establishes a pharmacological and theoretical foundation for understanding OA's anti-tumor effects and future therapeutic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.